For those at Antibody Engineering & Therapeutics Europe, @ManifoldBio AI Protein Design scientist Mike Nichols is in Basel this week giving a talk on mBER, our open-source AI protein design method. Mike will share results from the largest de novo antibody design campaign reported to date: 1M VHH binders designed against 436 targets, achieving 45% target success. mBER designs binders in defined formats, outputting both sequences and predicted binding structures. Paired with in vivo multiplexed screening, it forms Manifold’s direct-to-vivo drug discovery platform, taking AI-designed molecules straight to in vivo readouts. 📅 Friday May 29, 2026 | 11:30am CET | Basel, Switzerland 📍@ Antibody Engineering & Therapeutics Europe

Great to see Manifold’s #mBER AI protein design model in action! As part of the Amazon Bio Discovery launch this week, @AmazonScience performed agent-guided de novo design using three independent methods including @ManifoldBio 's #mBER to design nanobody binders against a novel cancer target, identifying several sub-nanomolar hits. mBER is now available via Amazon Bio Discovery.

AI is catalyzing the greatest acceleration of engineering capability in human history. Drug discovery, still serial by nature, hasn't kept pace. One molecule, one experiment at a time, starved of data at the right scale and physiological relevance to fuel AI-guided design. @ManifoldBio is making biology massively parallel, testing hundreds of thousands of drug designs simultaneously in a single experiment, including in living systems. We use this data to build organism-scale models of biology, which, combined with our AI-guided molecular design, power a fundamentally new approach to drug development. We're honored to be named one of @FastCompany 's Most Innovative Companies of 2026. This recognition reflects what's been an extraordinary year for the team: - Broke the 100,000-plex barrier for massively parallel in vivo studies - Released mBER, a state-of-the-art de novo antibody design model - Secured a $2B ($55M upfront) partnership with Roche, the biggest AI x Bio deal of the past 4 years - Ran a world-first with @NVIDIAHealth : 1 million AI-designed binders. 127 targets. 100M protein-protein interactions. One experiment. We're bringing biology into the digital realm. This is just the beginning.

If you're at #ADPD2026, don't miss Naveen Mehta’s talk on @ManifoldBio’s approach to one of the core challenges in treating neurodegenerative diseases: getting drugs across the blood-brain barrier.

Underlying this work, and central to Manifold's pipeline of tissue-targeted medicines, is our multiplexed in vivo screening platform that allows simultaneous assessment of tissue distribution across hundreds of receptor candidates in a single study.

@ManifoldBio and @NVIDIAHealth announce a joint study validating Proteina-Complexa, NVIDIA's latest BioNeMo model for protein binder design.

This method was first demonstrated by @ManifoldBio last October. We tested 1.1M VHH antibody designs against 145 targets, measuring 100M protein-protein interactions to validate #mBER, the company’s AI library for designing epitope-specific antibodies. 👉 manifold.bio/news/introducin…